Literature DB >> 16075928

Circulating insulin-like growth factor-I levels are correlated with the atherosclerotic profile in healthy subjects independently of age.

A Colao1, S Spiezia, C Di Somma, R Pivonello, P Marzullo, F Rota, T Musella, R S Auriemma, M C De Martino, G Lombardi.   

Abstract

To investigate the relationships between the GH-IGF-I axis and the atherosclerotic profile, we designed this open, observational, prospective study. Peak GH after GHRH+arginine (ARG) test, serum IGF-I and IGF binding protein-3 (IGFBP-3), lipid profile, homeostasis model assessment (HOMA) index and intima-media thickness (IMT) at common carotid arteries were measured in 174 healthy individuals (92 women, 82 men, aged 18-80 yr). Exclusion criteria for this study were: 1) body mass index (BMI) > or = 30 kg/m2; 2) personal history of cardiovascular diseases; 3) previous or current treatments of diabetes or hypertension; 4) previous corticosteroids treatment for longer than 2 weeks or estrogens for longer than 3 months; 5) smoking of more than 15 cigarettes/day and alcohol abuse. Subjects were divided according to age in decade groups from < 20 to > 70 yr. BMI increased with age, as did systolic and diastolic blood pressures, although they remained in the normal range. The GH peak after GHRH+ARG test was significantly higher in the subjects aged < 20 yr than in all the other groups (p < 0.01), but was similar in the remaining groups. An inverse correlation was found between the IGF-I z-score and total/HDL-cholesterol ratio (p = 0.02) and mean IMT (p = 0.0009); IGFBP-3 z-score and mean IMT (p = 0.043); IGF: IGFBP-3 molar ratio and total/HDL-cholesterol ratio (p < 0.0001) and mean IMT (p < 0.0001). Atherosclerotic plaques were found in 7 out of 12 subjects (53.8%) with a z-IGF-I score from < or = -2 to -1, in 4 out of 63 (6.3%) with a z-IGF-I score from -0.99 to 0.1 out of 66 (1.5%) with a z-IGF-I score from 0.1 to 1 and none of the 33 subjects with an IGF-I z-score >1 (p = 0.006). At multi-step regression analysis, age was the best predictor of HDL-cholesterol levels and mean IMT, IGF-I level was the best predictor of total cholesterol and total/HDL-cholesterol ratio, the IGF-I/IGFBP-3 molar ratio was the best predictor of triglycerides levels. The z-scores of IGF-I and IGFBP-3 were the second best predictors of mean IMT after age. In conclusion, IGF-I and IGFBP-3 were negatively correlated with common cardiovascular risk factors, studied as total/HDL-cholesterol ratio, and/or early atherosclerosis, studied as IMT at common carotid arteries. The prevalence of atherosclerotic plaques, though not hemodinamically significant, was higher in the subjects having a z-score of IGF-I of < or = -2 to -1. Our results support a role of the IGF/IGFBP-3 axis in the pathogenesis of atherosclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16075928     DOI: 10.1007/bf03347225

Source DB:  PubMed          Journal:  J Endocrinol Invest        ISSN: 0391-4097            Impact factor:   4.256


  40 in total

1.  Intima-media thickness in cardiovascularly asymptomatic hypopituitary adults with growth hormone deficiency: relation to body mass index, gender, and other cardiovascular risk factors.

Authors:  Maria Leonsson; Johannes Hulthe; Jan Oscarsson; Gudmundur Johannsson; Inger Wendelhag; John Wikstrand; Bengt-Ake Bengtsson
Journal:  Clin Endocrinol (Oxf)       Date:  2002-12       Impact factor: 3.478

2.  Cardiovascular disease and insulin-like growth factor I.

Authors:  Jan Frystyk; Thomas Ledet; Niels Møller; Allan Flyvbjerg; Hans Orskov
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

3.  Comparison between insulin-induced hypoglycemia and growth hormone (GH)-releasing hormone + arginine as provocative tests for the diagnosis of GH deficiency in adults.

Authors:  G Aimaretti; G Corneli; P Razzore; S Bellone; C Baffoni; E Arvat; F Camanni; E Ghigo
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

4.  Growth hormone (GH) responsiveness to combined administration of arginine and GH-releasing hormone does not vary with age in man.

Authors:  E Ghigo; S Goffi; M Nicolosi; E Arvat; F Valente; E Mazza; M C Ghigo; F Camanni
Journal:  J Clin Endocrinol Metab       Date:  1990-12       Impact factor: 5.958

5.  Growth hormone (GH) treatment reverses early atherosclerotic changes in GH-deficient adults.

Authors:  M Pfeifer; R Verhovec; B Zizek; J Prezelj; P Poredos; R N Clayton
Journal:  J Clin Endocrinol Metab       Date:  1999-02       Impact factor: 5.958

6.  Detection of premature atherosclerosis by high-resolution ultrasonography in symptom-free hypopituitary adults.

Authors:  V Markussis; S A Beshyah; C Fisher; P Sharp; A N Nicolaides; D G Johnston
Journal:  Lancet       Date:  1992-11-14       Impact factor: 79.321

7.  Early vascular alterations in acromegaly.

Authors:  Gregorio Brevetti; Paolo Marzullo; Antonio Silvestro; Rosario Pivonello; Gabriella Oliva; Carolina di Somma; Gaetano Lombardi; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2002-07       Impact factor: 5.958

8.  Insulin-like growth factor-I and angiographically documented coronary artery disease.

Authors:  P Spallarossa; C Brunelli; F Minuto; D Caruso; M Battistini; S Caponnetto; R Cordera
Journal:  Am J Cardiol       Date:  1996-01-15       Impact factor: 2.778

9.  Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study.

Authors:  Anders Juul; Thomas Scheike; Michael Davidsen; Jesper Gyllenborg; Torben Jørgensen
Journal:  Circulation       Date:  2002-08-20       Impact factor: 29.690

10.  Premature mortality due to cardiovascular disease in hypopituitarism.

Authors:  T Rosén; B A Bengtsson
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

View more
  12 in total

1.  Cardiovascular risk in adult hypopituitaric patients with growth hormone deficiency: is there a role for vitamin D?

Authors:  Maria Cristina Savanelli; Elisabetta Scarano; Giovanna Muscogiuri; Luigi Barrea; Laura Vuolo; Manila Rubino; Silvia Savastano; Annamaria Colao; Carolina Di Somma
Journal:  Endocrine       Date:  2015-10-29       Impact factor: 3.633

2.  Effects of ACE-inhibition on IGF-1 and IGFBP-3 concentrations in older adults with high cardiovascular risk profile.

Authors:  S Giovannini; M Cesari; E Marzetti; C Leeuwenburgh; M Maggio; M Pahor
Journal:  J Nutr Health Aging       Date:  2010-06       Impact factor: 4.075

3.  Circulating insulin-like growth factor-1 and its binding protein-3: metabolic and genetic correlates in the community.

Authors:  Carolyn S P Lam; Ming-Huei Chen; Sean M Lacey; Qiong Yang; Lisa M Sullivan; Vanessa Xanthakis; Radwan Safa; Holly M Smith; Xuyang Peng; Douglas B Sawyer; Ramachandran S Vasan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2010-04-08       Impact factor: 8.311

4.  Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease.

Authors:  Tatsuki Ichikawa; Kazuhiko Nakao; Keisuke Hamasaki; Ryuji Furukawa; Shotarou Tsuruta; Yasuo Ueda; Naota Taura; Hidetaka Shibata; Masumi Fujimoto; Kan Toriyama; Katsumi Eguchi
Journal:  Hepatol Int       Date:  2007-06-01       Impact factor: 6.047

5.  NADPH oxidases regulate CD44 and hyaluronic acid expression in thrombin-treated vascular smooth muscle cells and in atherosclerosis.

Authors:  Aleksandr E Vendrov; Nageswara R Madamanchi; Xi-Lin Niu; Kimberly C Molnar; Mason Runge; Cédric Szyndralewiez; Patrick Page; Marschall S Runge
Journal:  J Biol Chem       Date:  2010-06-17       Impact factor: 5.157

6.  Induction of cellular senescence by insulin-like growth factor binding protein-5 through a p53-dependent mechanism.

Authors:  Kwang Seok Kim; Young Bae Seu; Suk-Hwan Baek; Mi Jin Kim; Keuk Jun Kim; Jung Hye Kim; Jae-Ryong Kim
Journal:  Mol Biol Cell       Date:  2007-09-05       Impact factor: 4.138

7.  A retrospective analysis on biochemical parameters, cardiovascular risk and cardiomyopathy in elderly acromegalic patients.

Authors:  A Colao; R Pivonello; L Spinelli; M Galderisi; R S Auriemma; M Galdiero; G Vitale; M De Leo; G Lombardi
Journal:  J Endocrinol Invest       Date:  2007-06       Impact factor: 4.256

8.  Prevalence of the metabolic syndrome in moderately-severely obese subjects with and without growth hormone deficiency.

Authors:  C Di Somma; R Pivonello; G Pizza; A De Rosa; G Lombardi; A Colao; S Savastano
Journal:  J Endocrinol Invest       Date:  2009-09-30       Impact factor: 4.256

9.  Insulin Like Growth Factor Binding Protein-5 Regulates Excessive Vascular Smooth Muscle Cell Proliferation in Spontaneously Hypertensive Rats via ERK 1/2 Phosphorylation.

Authors:  Dong Hyup Lee; Jung Eun Kim; Young Jin Kang
Journal:  Korean J Physiol Pharmacol       Date:  2013-04-10       Impact factor: 2.016

10.  The role of insulin-like growth factor-1 in development of coronary no-reflow and severity of coronary artery disease in patients with acute myocardial infarction.

Authors:  Ibrahim Faruk Akturk; Ahmet Arif Yalcin; Ismail Biyik; Nihan Turhan Caglar; Nilgun Isiksacan; Cetin Sarikamis; Fatih Uzun; Omer Celik; Ilker Murat Caglar
Journal:  Postepy Kardiol Interwencyjnej       Date:  2014-03-23       Impact factor: 1.426

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.